The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice
- 29 February 2000
- journal article
- Published by Elsevier BV in Reproductive Toxicology
- Vol. 14 (1), 37-44
- https://doi.org/10.1016/s0890-6238(99)00065-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenThe New England Journal of Medicine, 1997
- Effects of raloxifene hydrochloride on the endometrium of postmenopausal womenAmerican Journal of Obstetrics and Gynecology, 1997
- Toremifene in Postmenopausal Breast CancerDrugs & Aging, 1997
- Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1996
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized ratsThe FASEB Journal, 1996
- Clinical Uses of AntiestrogensObstetrical & Gynecological Survey, 1996
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.JCI Insight, 1994
- Changes in the ovary of the mouse following exposure to X-rays. Part I.—Irradiation at three weeks oldProceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 1927